CD19 and systemic lupus erythematosus: These clinical studies investigating the efficiency of CD19-targeted CAR-T cell therapy on refractory cases of SLE shared a similar conditioning regimen comprised of fludarabine and cyclophosphamide and administered 1–1.1 × 106 autologous CAR-T cells/kg body weight.